SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from ...
The biotech industry needs to stop waiting for a rebound. The pandemic changed everything, though not in the ways most people ...
Valneva and Pfizer's three-dose shot targets the outer surface protein A (OspA) of the Borrelia burgdorfii bacteria that ...
On 25 March, detailed Phase I trial data was published for ESO-T01, AstraZeneca’s in vivo CAR-T therapy, in patients with ...
Since then, federal authorities have funded AIDS research and HIV prevention programs – but the Trump administration cut over ...
Explore how parenteral manufacturing solutions are evolving for specific drug formulations and meeting the demands of ...
The board of directors of Grayson-Jockey Club Research Foundation announced that it has authorized expenditure of $1,835,879 ...
Despite the study missing its primary endpoint, Pfizer will continue with the regulatory submission of the vaccine.
Six years later, the true scale of the vaccines’ side effects is emerging. Yet those coping with life-changing conditions ...
A federal judge has stayed the Trump administration’s revised childhood immunization schedule and frozen 13 ACIP appointments ...
Arrowhead Pharmaceuticals transitions from a 'show-me' pipeline to commercial- tage, with its first approval for plozasiran ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results